Drugs@FDA: FDA-Approved Drugs
Company: MYLAN INSTITUTIONAL
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
|---|---|---|---|---|---|---|---|
| ULTIVA | REMIFENTANIL HYDROCHLORIDE | EQ 1MG BASE/VIAL | INJECTABLE;INJECTION | Prescription | AP | Yes | No |
| ULTIVA | REMIFENTANIL HYDROCHLORIDE | EQ 2MG BASE/VIAL | INJECTABLE;INJECTION | Prescription | AP | Yes | No |
| ULTIVA | REMIFENTANIL HYDROCHLORIDE | EQ 5MG BASE/VIAL | INJECTABLE;INJECTION | Prescription | AP | Yes | Yes |
Original Approvals or Tentative Approvals
| Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
|---|---|---|---|---|---|---|---|
| 07/12/1996 | ORIG-1 | Approval | Type 1 - New Molecular Entity | STANDARD |
Review (PDF)
|
Label is not available on this site. |
https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020630Orig1s000rev.pdf |
Supplements
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
|---|---|---|---|---|---|
| 12/22/2025 | SUPPL-33 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/020630s031s033lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/020630Orig1s031,s033ltr.pdf | |
| 12/22/2025 | SUPPL-31 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/020630s031s033lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/020630Orig1s031,s033ltr.pdf | |
| 12/15/2023 | SUPPL-30 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020630s030lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/020630Orig1s030ltr.pdf | |
| 10/07/2019 | SUPPL-20 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020630s020lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/020630Orig1s020ltr.pdf | |
| 06/21/2018 | SUPPL-18 | Labeling-Package Insert, Labeling-Container/Carton Labels |
Label (PDF)
|
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020630s018lbl.pdf | |
| 12/16/2016 | SUPPL-16 | Labeling-Package Insert, Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020630s016lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/020630Orig1s016ltr.pdf | |
| 01/12/2016 | SUPPL-15 | Manufacturing (CMC) |
Label is not available on this site. |
||
| 06/11/2013 | SUPPL-14 | Manufacturing (CMC) |
Label is not available on this site. |
||
| 10/03/2002 | SUPPL-9 | Manufacturing (CMC) |
Label is not available on this site. |
||
| 12/20/2002 | SUPPL-8 | Manufacturing (CMC) |
Label is not available on this site. |
||
| 11/19/2001 | SUPPL-7 | Manufacturing (CMC) |
Label is not available on this site. |
||
| 09/19/2000 | SUPPL-6 | Manufacturing (CMC)-Control |
Label is not available on this site. |
||
| 03/08/2004 | SUPPL-5 | Efficacy-New Patient Population |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20630se5-005_ultiva_lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/20630se5-005ltr.pdf | |
| 06/23/1999 | SUPPL-3 | Labeling |
Label is not available on this site. |
||
| 11/23/1999 | SUPPL-2 | Efficacy-Labeling Change With Clinical Data |
Label is not available on this site. |
||
| 10/15/1999 | SUPPL-1 | Efficacy-New Patient Population |
Label is not available on this site. |
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
|---|---|---|---|---|---|
| 12/22/2025 | SUPPL-33 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/020630s031s033lbl.pdf | |
| 12/22/2025 | SUPPL-31 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/020630s031s033lbl.pdf | |
| 12/15/2023 | SUPPL-30 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020630s030lbl.pdf | |
| 10/07/2019 | SUPPL-20 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020630s020lbl.pdf | |
| 06/21/2018 | SUPPL-18 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020630s018lbl.pdf | |
| 06/21/2018 | SUPPL-18 | Labeling-Container/Carton Labels | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020630s018lbl.pdf | |
| 12/16/2016 | SUPPL-16 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020630s016lbl.pdf | |
| 12/16/2016 | SUPPL-16 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020630s016lbl.pdf | |
| 03/08/2004 | SUPPL-5 | Efficacy-New Patient Population | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20630se5-005_ultiva_lbl.pdf |
ULTIVA
INJECTABLE;INJECTION; EQ 1MG BASE/VIAL
TE Code = AP
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
|---|---|---|---|---|---|---|---|---|
| REMIFENTANIL HYDROCHLORIDE | REMIFENTANIL HYDROCHLORIDE | EQ 1MG BASE/VIAL | INJECTABLE;INJECTION | Prescription | No | AP | 206223 | FRESENIUS KABI USA |
| REMIFENTANIL HYDROCHLORIDE | REMIFENTANIL HYDROCHLORIDE | EQ 1MG BASE/VIAL | INJECTABLE;INJECTION | Prescription | No | AP | 210594 | HIKMA |
| REMIFENTANIL HYDROCHLORIDE | REMIFENTANIL HYDROCHLORIDE | EQ 1MG BASE/VIAL | INJECTABLE;INJECTION | Prescription | No | AP | 215635 | NIVAGEN PHARMS INC |
| ULTIVA | REMIFENTANIL HYDROCHLORIDE | EQ 1MG BASE/VIAL | INJECTABLE;INJECTION | Prescription | Yes | AP | 020630 | MYLAN INSTITUTIONAL |
INJECTABLE;INJECTION; EQ 2MG BASE/VIAL
TE Code = AP
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
|---|---|---|---|---|---|---|---|---|
| REMIFENTANIL HYDROCHLORIDE | REMIFENTANIL HYDROCHLORIDE | EQ 2MG BASE/VIAL | INJECTABLE;INJECTION | Prescription | No | AP | 206223 | FRESENIUS KABI USA |
| REMIFENTANIL HYDROCHLORIDE | REMIFENTANIL HYDROCHLORIDE | EQ 2MG BASE/VIAL | INJECTABLE;INJECTION | Prescription | No | AP | 210594 | HIKMA |
| REMIFENTANIL HYDROCHLORIDE | REMIFENTANIL HYDROCHLORIDE | EQ 2MG BASE/VIAL | INJECTABLE;INJECTION | Prescription | No | AP | 215635 | NIVAGEN PHARMS INC |
| ULTIVA | REMIFENTANIL HYDROCHLORIDE | EQ 2MG BASE/VIAL | INJECTABLE;INJECTION | Prescription | Yes | AP | 020630 | MYLAN INSTITUTIONAL |
INJECTABLE;INJECTION; EQ 5MG BASE/VIAL
TE Code = AP
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
|---|---|---|---|---|---|---|---|---|
| REMIFENTANIL HYDROCHLORIDE | REMIFENTANIL HYDROCHLORIDE | EQ 5MG BASE/VIAL | INJECTABLE;INJECTION | Prescription | No | AP | 206223 | FRESENIUS KABI USA |
| REMIFENTANIL HYDROCHLORIDE | REMIFENTANIL HYDROCHLORIDE | EQ 5MG BASE/VIAL | INJECTABLE;INJECTION | Prescription | No | AP | 210594 | HIKMA |
| REMIFENTANIL HYDROCHLORIDE | REMIFENTANIL HYDROCHLORIDE | EQ 5MG BASE/VIAL | INJECTABLE;INJECTION | Prescription | No | AP | 215635 | NIVAGEN PHARMS INC |
| ULTIVA | REMIFENTANIL HYDROCHLORIDE | EQ 5MG BASE/VIAL | INJECTABLE;INJECTION | Prescription | Yes | AP | 020630 | MYLAN INSTITUTIONAL |